Insmed (INSM) Non-Current Assets (2010 - 2026)
Insmed (INSM) recorded quarterly Non-Current Assets of $462.7 million in Q1 2026, down 1.63% quarter-over-quarter from $470.4 million in Q4 2025, and up 15.66% on a YoY basis from $400.0 million in Q1 2025.
Insmed (INSM) Non-Current Assets (2010 - 2026) Analysis & Trends
Insmed's Non-Current Assets history runs 17 years deep, the most recent figure standing at $462.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 15.66% year-over-year to $462.7 million; the TTM figure through Mar 2026 stood at $1.8 billion (up 10.11% YoY), while the FY2025 annual figure was $470.4 million, up 16.55% from the prior year.
- Non-Current Assets was $462.7 million for Q1 2026 at Insmed, down from $470.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $470.4 million in Q4 2025 to a low of $362.7 million in Q3 2022.
- Historically, Non-Current Assets has averaged $403.2 million across 5 years, with a median of $398.3 million in 2023.
- Biggest YoY gain for Non-Current Assets was 107.52% in 2022; the steepest drop was 5.76% in 2022.
- A 5-year view of Non-Current Assets shows it stood at $383.1 million in 2022, then climbed by 4.63% to $400.8 million in 2023, then rose by 0.7% to $403.6 million in 2024, then increased by 16.55% to $470.4 million in 2025, then dropped by 1.63% to $462.7 million in 2026.
- The last three Non-Current Assets figures came in at $462.7 million (Q1 2026), $470.4 million (Q4 2025), and $428.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 39.71 Mn |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | 462.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 462.69 Mn |
| Dec 31, 2025 | 470.35 Mn |
| Sep 30, 2025 | 428.93 Mn |
| Jun 30, 2025 | 398.28 Mn |
| Mar 31, 2025 | 400.04 Mn |
| Dec 31, 2024 | 403.57 Mn |
| Sep 30, 2024 | 403.13 Mn |
| Jun 30, 2024 | 391.93 Mn |
| Mar 31, 2024 | 400.37 Mn |
| Dec 31, 2023 | 400.77 Mn |
| Sep 30, 2023 | 398.30 Mn |
| Jun 30, 2023 | 386.72 Mn |
| Mar 31, 2023 | 388.65 Mn |
| Dec 31, 2022 | 383.05 Mn |
| Sep 30, 2022 | 362.65 Mn |
| Jun 30, 2022 | 378.63 Mn |
| Mar 31, 2022 | 397.18 Mn |
| Dec 31, 2021 | 406.47 Mn |
| Sep 30, 2021 | 352.79 Mn |
| Jun 30, 2021 | 191.59 Mn |